CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

If you're an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech stock ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Synthego granted global license to manufacture and distribute AZ's CRISPR gene editing enzyme, eSpOT-ON.

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

Anticipated 2025 milestones include: declare two in vivo development candidates, one in HSCs and one in liver; present further in vivo HSC data; present in vivo data in one liver indication; establish ...

ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...

Continue advancing our pipeline candidates, with several key updates in 2025, including CTX112™ in oncology and autoimmune ...